Abstract
Hypertension, a global public health problem, is currently the leading factor in the global burden of disease. It is the major modifiable risk factor for heart disease, stroke and kidney failure. Chronic kidney disease (CKD) is both a common cause of hypertension and CKD is also a complication of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. This is particularly significant in the setting of resistant hypertension commonly seen in patient with CKD. The pathophysiology of CKD associated hypertension is multi-factorial with different mechanisms contributing to hypertension. These pathogenic mechanisms include sodium dysregulation, increased sympathetic nervous system and alterations in renin angiotensin aldosterone system activity. Standardized blood pressure (BP) measurement is essential in establishing the diagnosis and management of hypertension in CKD. Use of ambulatory blood pressure monitoring provides an additional assessment of diurnal variation in BP commonly seen in CKD patients. The optimal BP target in the treatment of hypertension in general and CKD population remains a matter of debate and controversial despite recent guidelines and clinical trial data. Medical therapy of patients with CKD associated hypertension can be difficult and challenging. Additional evaluation by a hypertension specialist may be required in the setting of treatment resistant hypertension by excluding pseudo-resistance and treatable secondary causes. Treatment with a combination of antihypertensive drugs, including appropriate diuretic choice, based on estimated glomerular filtration rate, is a key component of hypertension management in CKD patients. In addition to drug treatment non-pharmacological approaches including life style modification, most important of which is dietary salt restriction, should be included in the management of hypertension in CKD patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agarwal R (2006) Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. Curr Opin Nephrol Hypertens 15:309–313
Agarwal R, Andersen MJ (2006) Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 69:1175–1180
Agarwal R, Pappas MK, Sinha AD (2016) Masked uncontrolled hypertension in CKD. J Am Soc Nephrol 27:924–932
Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernandez-Sola J, Urbano-Marquez A (1999) Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 33:653–657
American Diabetes Association (2013) Standards of medical care in diabetes—2013. Diabetes Care 36:S11–S66
American Heart Association: Shaking the salt habit. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Shaking-the-Salt-Habit
Anderson S, Brenner BM (1988) Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens 1:380S–383S
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM et al (1997) A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117–1124
Araujo M, Wilcox CS (2014) Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal 20:74–101
Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J (2005) Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 45:1035–1041
Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A (2004) Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65:1991–2002
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K et al (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401
Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA (2013) Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 22:1–9
Boudville N, Ward S, Benaroia M, House AA (2005) Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 18:1300–1305
Briet M, Schiffrin EL (2013) Vascular actions of aldosterone. J Vasc Res 50:89–99
Briet M, Boutouyrie P, Laurent S, London GM (2012) Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 82:388–400
Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Møller B et al (2012) Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension 60:1346–1351
Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J (2013) Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 62:218–225
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51:1403–1419
Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y et al (2014) Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 63:259–264
Ciobanu AO, Gherghinescu CL, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M et al (2013) The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. Maedica 8:129–136
Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G (2014) Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 63:692–697
Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL (2012) Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and metaanalysis. Lancet 379:905–914
Cohen DL, Huan Y, Townsend RR (2014) Home blood pressure monitoring in CKD. Am J Kidney Dis 63:835–842
Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C et al (2000) Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 36:461–465
Crowley SD (2014) The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid Redox Signal 20:102–120
Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585
Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V et al (2001) High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 19:2063–2070
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366:895–906
Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS et al (2014) The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30:485–501
Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al (2012) Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125:1635–1642
Davis JO, Freeman RH (1976) Mechanisms regulating renin release. Physiol Rev 56:1–56
de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al (2011) Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57:898–902
De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V et al (2013) Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61:2461–2467
DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77:75–197
Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S et al (2005) Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46:156–161
Drawz PE, Abdalla M, Rahman M (2012) Blood pressure measurement: clinic, home, ambulatory, and beyond. Am J Kidney Dis 60:449–462
Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J et al (2016) Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol 11:642–652
Dudenbostel T, Calhoun DA (2012) Resistant hypertension, obstructive sleep apnea and aldosterone. J Hum Hypertens 26:281–287
Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A et al (2003) Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100:14211–14216
Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22:2217–2226
Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB et al (2006) Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47:352–358
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension. (The Symplicity HTN-2 Trial) a randomized controlled trial. Lancet 376:1903–1909
Fagard RH, Cornelissen VA (2007) Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 25:2193–2198
Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr et al (2010) Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56:780–800
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892–1903
Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM et al (2010) Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 6:363–368
Grossman E, Messerli FH (2012) Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 125:14–22
Hall JE (2003) The kidney, hypertension, and obesity. Hypertension 41:625–633
Hänninen MR, Niiranen TJ, Puukka PJ, Kesäniemi YA, Kähönen M, Jula AM (2013) Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens 31:1136–1143
Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA et al (2012) Renal denervation in moderate to severe CKD. J Am Soc Nephrol 23:1250–1257
Hermida RC, Diana E, Ayala DE, Mojón A, Fernández JR (2011a) Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22:2313–2321
Hermida RC, Ayala DE, Mojon A, Fernandez JR (2011b) Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 58:1165–1173
Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287
Hoorn EJ, Walsh SB, McCormick JA, Fürstenberg A, Yang CL, Roeschel T et al (2011) The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 17:1304–1309
Hovater MB, Sanders PW (2012) Effect of dietary salt on regulation of TGF-beta in the kidney. Semin Nephrol 32:269–276
Izzo JL (2012) Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and reninangiotensin-aldosterone blockade. J Clin Hypertens 14:344
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520
Johnson AG, Nguyen TV, Day RO (1994) Do nonsteroidal anti-inflammatory drugs affect blood pressure? Meta-Analysis Ann Intern Med 121:289–300
Kanno A, Kikuya M, Asayama K, Satoh M, Inoue R, Hosaka M et al (2013) Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the Ohasama Study. J Hypertens 31:2410–2417
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2:337–414
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877–884
Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ (2003) Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14:3239–3244
Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ (1982) Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4:190–197
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281
Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ et al (2014) Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol 2:385–395
LeLorier J, Bombardier C, Burgess E, Moist L, Wright N, Cartier P et al (2002) Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol 18:1301–1308
Lohmeier TE, Iliescu R (2015) The baroreflex as a long-term controller of arterial pressure. Physiology 30:148–158
Lohmeier TE, Liu B, Hildebrandt DA, Cates AW, Georgakopoulos D, Irwin ED (2015) Global- and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension 65:1223–1230
Luft FC, Weinberger MH (1988) Review of salt restriction and the response to antihypertensive drugs: satellite symposium on calcium antagonists. Hypertension 11:I-229–32
Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF et al (2011) Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 26:2827–2847
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357
Mansoor GA (2001) Herbs and alternative therapies in the hypertension clinic. Am J Hypertens 14:971–975
McCullough PA, Steigerwalt S, Tolia K, Chen SC, Li S, Norris KC et al (2011) Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep 11:47–55
Mojón A, Ayala DE, Piñeiro L, Otero A, Crespo JJ, Moyá A et al (2013) Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 30:145–158
Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C et al (2013) Resistant hypertension and target organ damage. Hypertens Res 36:485–491
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G et al (2010) Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 55:441–451
Murray CJ, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369:448–457
Muxfeldt ES, Salles GF (2008) Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens 26:878–884
Muxfeldt ES, Cardoso CR, Salles GF (2009) Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 169:874–880
National Institute for Health and Care Excellence. Chronic kidney disease. http://www.nice.org.uk/guidance/cg182/evidence/cg182-chronic-kidney-disease
National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/cg127/resources/guidancehypertension
Nicholl DD, Ahmed SB, Loewen AH, Hemmelgarn BR, Sola DY, Beecroft JM et al (2012) Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 141:1422–1430
Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM (2010) Home measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 55:1346–1351
Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16:925–930
Ogedegbe G, Schoenthaler A (2006) A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens 8:174–180
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559
Ott C, Mahfoud F, Schmid A, Toennes SW, Ewen S, Ditting T et al (2015) Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens 33:1261–1266
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213
Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 370:829–840
Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE et al (2012) Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med 172:41–47
Persu A, O’Brien E, Verdecchia P (2014) Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. Hypertens Res 37:967–972
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN et al (2005) Recommendations of blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation 111:697–716
Pickkers P, Hughes AD, Russel FG, Thien T, Smits P (1998) Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 32:1071–1076
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ et al (2009) Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54:475–481
Rimoldi SF, Scherrer U, Messerli FH (2014) Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 35:1245–1254
Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS et al (2015) Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 65:1372–1407
Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M et al (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365:939–946
Sakhuja A, Textor SC, Taler SJ (2015) Uncontrolled hypertension by the evidence-based guideline: results from NHANES 2011–2012. J Hypertens 33:644–651
Shankar SS, Brater DC (2003) Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284:F11–F21
Sica DA (2008) The kidney and hypertension: causes and treatment. J Clin Hypertens 10:541–548
Singer DR, Markandu ND, Sugden AL, Miller MA, MacGregor GA (1991) Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension 17:798–803
Siu AL (2015) U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 163:778–786
Somers VK, Dyken ME, Clary MP, Abboud FM (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96:1897–1904
SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116
Svenningsen P, Friis UG, Versland JB, Buhl KB, Møller Frederiksen B, Andersen H et al (2013) Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol 207:536–545
Tamargo J, Segura J, Ruilope LM (2014a) Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 15:527–547
Tamargo J, Segura J, Ruilope LM (2014b) Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 15:605–621
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR et al (2013) Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 8:1583–1590
Upadhyay A, Earley A, Haynes SM, Uhlig K (2011) Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154:541–548
Uzu T, Kimura G (1999) Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100:1635–1638
Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG et al (2001) Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 135:1019–1028
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al (2014a) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 16:14–26
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al (2014b) Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32:3–15
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE et al (2012) Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int 81:568–576
Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC et al (2008) CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51:S13–S20
Whelton SP, Chin A, Xin X, He J (2002) Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 136:493–503
Wildman RP, Gu D, Muntner P, Huang G, Chen J, Duan X et al (2005) Alcohol intake and hypertension subtypes in Chinese men. J Hypertens 23:737–743
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068
World Health Organization (2013) A global brief on hypertension: silent killer, global public health crisis. World Health Day 2013. World Health Organization, Geneva, pp 1–39
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431
Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountlkalakis TD (2005) Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 12:243–249
Yoon SS, Fryar CD, Carroll MD (2015) Hypertension prevalence and control among adults: United States, 2011–2014, NCHS data brief, no 220. National Center for Health Statistics, Hyattsville
Ziegler MG, Milic M, Sun P (2011) Antihypertensive therapy for patients with obstructive sleep apnea. Curr Opin Nephrol Hypertens 20:50–55
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Hamrahian, S.M., Falkner, B. (2016). Hypertension in Chronic Kidney Disease. In: Islam, M.S. (eds) Hypertension: from basic research to clinical practice. Advances in Experimental Medicine and Biology(), vol 956. Springer, Cham. https://doi.org/10.1007/5584_2016_84
Download citation
DOI: https://doi.org/10.1007/5584_2016_84
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44250-1
Online ISBN: 978-3-319-44251-8
eBook Packages: MedicineMedicine (R0)